261 related articles for article (PubMed ID: 32280079)
1. Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
Douvdevani A; Bernstein-Molho R; Asraf K; Doolman R; Laitman Y; Friedman E
Cancer Biomark; 2020; 28(3):269-273. PubMed ID: 32280079
[TBL] [Abstract][Full Text] [Related]
2. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
3. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
5. The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
Laitman Y; Kuchenbaecker KB; Rantala J; Hogervorst F; Peock S; Godwin AK; Arason A; Kirchhoff T; Offit K; Isaacs C; Schmutzler RK; Wappenschmidt B; Nevanlinna H; Chen X; Chenevix-Trench G; Healey S; Couch F; Peterlongo P; Radice P; Nathanson KL; Caligo MA; Neuhausen SL; Ganz P; Sinilnikova OM; McGuffog L; Easton DF; Antoniou AC; Wolf I; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(3):1119-26. PubMed ID: 22212556
[TBL] [Abstract][Full Text] [Related]
6. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
7. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
8. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
9. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.
Widschwendter M; Rosenthal AN; Philpott S; Rizzuto I; Fraser L; Hayward J; Intermaggio MP; Edlund CK; Ramus SJ; Gayther SA; Dubeau L; Fourkala EO; Zaikin A; Menon U; Jacobs IJ
Lancet Oncol; 2013 Nov; 14(12):1226-32. PubMed ID: 24140203
[TBL] [Abstract][Full Text] [Related]
10. Incorporating tumour pathology information into breast cancer risk prediction algorithms.
Mavaddat N; Rebbeck TR; Lakhani SR; Easton DF; Antoniou AC
Breast Cancer Res; 2010; 12(3):R28. PubMed ID: 20482762
[TBL] [Abstract][Full Text] [Related]
11. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
Levy-Lahad E; Lahad A; Eisenberg S; Dagan E; Paperna T; Kasinetz L; Catane R; Kaufman B; Beller U; Renbaum P; Gershoni-Baruch R
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3232-6. PubMed ID: 11248061
[TBL] [Abstract][Full Text] [Related]
12. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?
Semple J; Metcalfe KA; Lubinski J; Huzarski T; Gronwald J; Armel S; Lynch HT; Karlan B; Foulkes W; Singer CF; Neuhausen SL; Eng C; Iqbal J; Narod SA;
Breast Cancer Res Treat; 2015 Nov; 154(1):163-9. PubMed ID: 26467043
[TBL] [Abstract][Full Text] [Related]
13. Antimüllerian hormone levels are lower in BRCA2 mutation carriers.
Johnson L; Sammel MD; Domchek S; Schanne A; Prewitt M; Gracia C
Fertil Steril; 2017 May; 107(5):1256-1265.e6. PubMed ID: 28476184
[TBL] [Abstract][Full Text] [Related]
14. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
15. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
[TBL] [Abstract][Full Text] [Related]
16. The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer.
Metcalfe KA; Lubinski J; Gronwald J; Huzarski T; McCuaig J; Lynch HT; Karlan B; Foulkes WD; Singer CF; Neuhausen SL; Senter L; Eisen A; Sun P; Narod SA;
Clin Genet; 2018 May; 93(5):1063-1068. PubMed ID: 29206279
[TBL] [Abstract][Full Text] [Related]
17. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and BRCA2 Germline Mutation Screening in Western Algeria using High Resolution Melting Analysis (HRM).
Boulenouar ACS; Coulet F; Bendiab FMT; Boudinar FZ; Senhadji R
Gulf J Oncolog; 2018 May; 1(27):31-37. PubMed ID: 30145549
[TBL] [Abstract][Full Text] [Related]
19. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
[TBL] [Abstract][Full Text] [Related]
20. The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients.
Bernstein-Molho R; Barnes-Kedar I; Ludman MD; Reznik G; Feldman HB; Samra NN; Eilat A; Peretz T; Peretz LP; Shapira T; Magal N; Kalis ML; Yerushalmi R; Vinkler C; Liberman S; Basel-Salmon L; Shohat M; Levy-Lahad E; Friedman E; Bazak L; Goldberg Y
Breast Cancer Res Treat; 2019 Nov; 178(1):231-237. PubMed ID: 31368036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
